Danaher Corporation DHR

LOL, yeah the smart people are stepping in….shrewd as always. Making $$

DHR was up and holding $320 on superb results, raised guidance and strong future earnings announcement. Bit players slowly selling….too bad for them. The smart and educated money will swoop in and grab this at such a discount.

DHR: $325-330 by Friday $355 EOY $390-$420 in FY22

DHR: DOV are direct competitors in many of the same business markets. Expect the same tomorrow from Danaher, that Dover just reported (see below). Another plus for DHR is is medical business which Dover does not have!!! Big upside for DHR coming.

Here is a portion of Dovers report;

Dover Corporation Grows Revenue And Widens Margins

Dover Corporation is managing its supply chain issues with aplomb and was able to deliver revenue and earnings above expectations. The company reported $2.01 billion in net consolidated revenue which is good for a gain of 14.9% over last year and beat the Marketbeat.com consensus estimate by 100 basis points. The company said it is seeing strength across all segments and expects to see the strength continue into the fourth quarter at least.

Moving down the report, results were not equal across the network but, on balance, the company was able to improve its operating margins by 165 basis points. The operating margin of 13.08% drove a 31% increase in the GAAP earnings which beat the consensus by $0.18 and includes investment in a capacity expansion that will boost revenue and earnings in future quarters. On an adjusted basis, the $1.98 was also strong and beat the consensus by $0.13.

Looking forward, the company is expecting strength to continue and has raised its guidance accordingly. The new guidance of $7.45 to $7.50 in adjusted earnings compares well with the previous consensus estimate of $7.42 and has shares moving higher.

“More positively, our high backlog levels provide beneficial near-term visibility for the remainder of the year and into 2022. As a result, we are raising our full-year EPS guidance,” concluded Tobin.

No bets, it will be close to $320 tomorrow, climbing to $330. All news is good, strong outlook for FY22. Minimal supply chain issues already worked out. As a former Director at DHR for 10 years, my sources are broad and accurate. Lets see what the market decides :))

DHR: heading into results $310, coming out of results $320, EOY $345, FY22 $395-$405
Trailing P/E is 40, forward P/E 31…..very low for a medical company, solid for an industrial company. A portfolio must have. Buy it, let it run, retire.

DHR: right on schedule. You want to be in before Thursday, but even then its still a buy.

DHR to report strong earnings across all platforms. Will mention supply line, but wont have a major affect on their growth or profitability. Will stay conservative with 2022 growth projections, but will increase profitability. Healthy PE at 31. Expect PT of 330 by eoy and 380 FY22. DHR remains strong as a defensive hold and a significant growth stock. They will return >20% stock price in FY22.

Ahh, another earnings call…..buy now or weep.

Rob, I was a Director for one of there companies for 10 years.